DG
23
2
RCL
77
-6
FOXA
53
8
LOW
46
-2
FLR
59
4
ADP
61
-3
DUK
37
-3
CMG
63
9
HON
58
3
BBY
40
2
STT
53
-11
AN
43
2
DE
40
-2
GIS
40
3
HSY
31
2
ES
53
-2
JWN
50
-2
SWK
64
3
MAT
60
-5
PPL
52
-7
DG
23
2
RCL
77
-6
FOXA
53
8
LOW
46
-2
FLR
59
4
ADP
61
-3
DUK
37
-3
CMG
63
9
HON
58
3
BBY
40
2
STT
53
-11
AN
43
2
DE
40
-2
GIS
40
3
HSY
31
2
ES
53
-2
JWN
50
-2
SWK
64
3
MAT
60
-5
PPL
52
-7
Financhill
Back

Aurora Cannabis 10K Form

Sell
40

ACB
Aurora Cannabis

Last Price:
5.99
Seasonality Move:
51.74%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ACB News And Ratings

See the #1 stock for the next 7 days that we like better than ACB

ACB Financial Statistics

Sales & Book Value

Annual Sales: $200.33M
Cash Flow: $2.35M
Price / Cash Flow: 0
Annual Sales: $7.50
Price / Book: 0.74

Profitability

EPS (TTM): -0.55020
Net Income (TTM): $-27.72M
Gross Margin: $97.44M
Return on Equity: -6.62%
Return on Assets: -4.5%

Aurora Cannabis Earnings Forecast

Key Aurora Cannabis Financial Ratios

  • The Gross Profit Margin over the past 17 years for ACB is 48.64%.
  • The Selling, General & Administrative Expenses for ACB have been equal to 58.04% of Gross Profit Margin.
  • The Research & Development expenses have been 1.32% of Revenue.
  • The Interest Expense is -20.46% of Operating Income.
  • The Net Earning history of ACB is -25.65% of Total Revenues.
  • Per Share Earnings over the last 18 years have been positive in 9 years.

Aurora Cannabis Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ACB
CUSIP: 05156X
Website: auroramj.com

Debt

Debt-to-Equity Ratio: 0.09
Current Ratio: 3.76
Quick Ratio: 1.25

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ACB Technical Analysis vs Fundamental Analysis

Sell
40
Aurora Cannabis (ACB) is a Sell

Is Aurora Cannabis a Buy or a Sell?

  • Aurora Cannabis stock is rated a Sell
    The current Aurora Cannabis [ACB] share price is $5.54. The Score for ACB is 40, which is 20% below its historic median score of 50, and infers higher risk than normal.